Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.

@article{Svendsen2004DoesTC,
  title={Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.},
  author={Kristina Bacher Svendsen and Troels Staehelin Jensen and Flemming W Bach},
  journal={BMJ},
  year={2004},
  volume={329 7460},
  pages={253}
}

• Kristina Bacher Svendsen, Troels Staehelin Jensen, Flemming W Bach
• Published 2004 in BMJ

OBJECTIVE To evaluate the effect of the oral synthetic delta-9-tetrahydrocannabinol dronabinol on central neuropathic pain in patients with multiple sclerosis. DESIGN Randomised double blind placebo controlled crossover trial. SETTING Outpatient clinic, University Hospital of Aarhus, Denmark. PARTICIPANTS 24 patients aged between 23 and 55 years with multiple sclerosis and central pain. INTERVENTION Orally administered dronabinol at a maximum dose of 10 mg daily or corresponding placebo… CONTINUE READING

Save to Library

Create Alert

Cite

View Paper